ForumIAS LATEST
- Prelims Test Series (PTS) for Prelims 2027 starts 11th Oct. 2026 Click Here to know more →
- [Pre-order] Ethics Redbook 3rd Edition: Delivery starts from 10th October onwards Click Here to Read More →
- 21 Sept. | Forum Residential Coaching (FRC) for UPSC preparation Click Here to know more →
- 21 Sept. | GS Advance Program (GSAP) for UPSC 2027 Mains starts from 10th Oct. Click Here to Read More →
- The Institute of Life Sciences(ILS) has successfully developed antibodies against the Chikungunya virus(CHIKV) infection.
- The antibodies were developed following decade-long research on the CHIKV infection at the ILS laboratory.
- With no prior antibodies reported against CHIKV,the group was the first to develop antibodies against the non-structural proteins – nsP1,nsP3 and nsP4 of CHIKV.
- This development is significant as it will help researchers who are working on CHIKV infection to understand the various aspects of virus pathogenesis.
- This will also pave the way for the development of antiviral drugs and control strategies against the infection.
- Chikungunya is a viral disease which is transmitted to humans by infected mosquitoes especially through Aedes aegypti and Aedes albopictus species of mosquitoes.
- These mosquitoes can be found biting throughout daylight hours though there may be peaks of activity in the early morning and late afternoon.It causes fever and severe joint pain.
- ILS is a premier research organization founded through a public–private partnership initiative in the year 2004.ILS has been accorded recognition as a Scientific & Industrial Research Organization(SIRO) by the Ministry of Science & Technology,Govt of India.



